Table 2. The effects of ERK1/2 inhibitors in PMA-administrated THP-1 cells.

	control	PD98059	PMA administration for 5 days
			—	PD98059
G0/G1 phase	19.6 ± 2.8%	20.5 ± 3.1%	70.3 ± 2.9%*	40.9 ± 5.4%*†
S phase	58.9 ± 6.2%	60.1 ± 7.5%	8.9 ± 3.1%*	15.9 ± 2.8%*†
G2/M phase	16.2 ± 8.8%	15.7 ± 6.8%	10.6 ± 0.8%*	43.2 ± 5.1%*

(n = 5). PD98059, ERK1/2 inhibitor. *p < 0.05 compared to control group; ^†p < 0.05 compared to PMA-administrated group.